[Ramucirumab-paclitaxel as second-line therapy for advanced gastric cancer: Poliambulanza experience].
We reported the cases of two patients affected by metastatic gastric cancer exposed to second line therapy with ramucirumab plus paclitaxel after progression. Both obtained a fast marker reduction with a very favourable toxicity profile. In the first case, a woman affected by peritoneal carcinomatosis, the disease had been stable for 8 months despite of the chemotherapy suspension after 3 cycles; whereas in the second case, a highly symptomatic man with a heavy tumor load (gastric tumor and multiple bone, node and peritoneal metastases) obtained an immediate clinical benefit even if of relatively short duration with a good tolerability.
UO di Oncologia, Fondazione Poliambulanza, Brescia, Italia.
Francesca
F
Aroldi
UO di Oncologia, Fondazione Poliambulanza, Brescia, Italia.
Chiara
C
Ogliosi
UO di Oncologia, Fondazione Poliambulanza, Brescia, Italia.
Alberto
A
Zaniboni
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols; D005260:Female; D006801:Humans; D008297:Male; D017239:Paclitaxel; D013274:Stomach Neoplasms; D000096662:Ramucirumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017239:Paclitaxel; D000096662:Ramucirumab